Painful diabetic neuropathy: an update

Area of Science:

• Neurology
• Endocrinology
• Pharmacology

Background:

• Diabetes mellitus is a primary cause of peripheral neuropathy.
• Approximately 50% of diabetic patients develop neuropathy over 25 years.
• Pathophysiology involves metabolic and vascular factors, including increased sorbitol, glycated endproducts, reactive oxygen species, and protein kinase C activation.

Purpose of the Study:

• To review the current understanding of painful diabetic neuropathy.
• To summarize existing and emerging therapeutic strategies for symptom management.
• To highlight the importance of glycemic control in managing diabetic neuropathy.

Main Methods:

• Literature review of studies on diabetic neuropathy.
• Analysis of pharmacological interventions for symptom relief.
• Discussion of emerging therapeutic targets and agents.

Main Results:

• Tight glycemic control is the first step in management.
• Antidepressants (TCAs, SNRIs) and certain anticonvulsants (pregabalin, gabapentin, lamotrigine) are effective for symptom control.
• Topical agents and local anesthetics also show good results, while opioids and NSAIDs are less preferred.

Conclusions:

• Currently, no drug can halt or reverse diabetic neuropathy progression.
• Therapies focus on symptomatic relief, with established agents like TCAs, SNRIs, and specific anticonvulsants offering efficacy.
• Novel therapies including NMDA antagonists, aldose reductase inhibitors, and alpha-lipoic acid are under investigation.